The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis
Open accessAbstract
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte‐free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion. We utilize a mathematical model to illustrate that electrolyte‐free water clearance results in a greater reduction in IF volume compared to blood volume, and that this difference may be mediated by peripheral sequestration of osmotically inactive sodium. By coupling the model with data on plasma and urinary sodium and water in healthy subjects who received either the SGLT2i dapagliflozin or loop diuretic bumetanide, we predict that dapagliflozin produces a 2‐fold greater reduction in IF volume compared to blood volume, while the reduction in IF volume with bumetanide is only 78% of the reduction in blood volume. Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment. Thus, we hypothesize that, by reducing IF volume to a greater extent than blood volume, SGLT2 inhibitors might provide better control of congestion without reducing arterial filling and perfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT-2i has a role of improving the multi-functional status of cardiovascular activities, although the diuretics seem to elicit a more powerful effect on reducing fluid retention.64,65”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [64]
In the citing paper
“In addition, a study that coupled plasma and urinary water and electrolyte data with mathematical modeling to compare effects of dapagliflozin and bumetanide on volumes of blood and interstitial fluid suggested that SGLT2 inhibitors have a preferential effect to mobilize fluid from the interstitial compartment rather than the intravascular space (38).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [38]
In the citing paper
“Mathematical analyses suggest that the excess electrolyte-free water clearance associated with osmotic diuresis may result in greater clearance of interstitial fluid compared with other forms of diuretics (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
In the citing paper
“This suggests that the capacity to store Na ϩ peripherally is associated with an ability to clear interstitial fluid, as we have described previously (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Francis, G. S., SIEGEL, R. M., Goldsmith, S. R., OLIVARI, M. T., Levine, T. B., & Cohn, J. N. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-1 · Cited by 577
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure
Weinfeld, M. S., Chertow, G. M., & Stevenson, L. W. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70113-4 · Cited by 279
Peacock, W. F., Costanzo, M. R., Marco, T. D., Lopatin, M., Wynne, J., Mills, R. M., & Emerman, C. L. (2008) · Cardiology · doi:10.1159/000164149 · Cited by 263
Body Fluid Volume Regulation in Health and Disease: A Unifying Hypothesis
Schrier, R. W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-155 · Cited by 263
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195
Greenberg, A. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40676-7 · Cited by 154
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 496
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
Butler, J., Zannad, F. M., FITCHETT, D. H., Zinman, B., Koitka‐Weber, A., von Eynatten, M., Zwiener, I., George, J. T., Brueckmann, M., Cheung, A. K., et al. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005875 · Cited by 49
Nakagawa, Y., & Kuwahara, K. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.03.009 · Cited by 52
Aguilar-Gallardo, J. S., Correa, A. A., & Contreras, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab056 · Cited by 51
Miyamoto, Y., Honda, A., Yokose, S., Nagata, M., & Miyamoto, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062253 · Cited by 48
Stoicescu, L., Crișan, D., Morgovan, C., Avram, L., & Ghibu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020794 · Cited by 57
A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability
Sher, A., Niederer, S., Mirams, G. R., Kirpichnikova, A., Allen, R., Pathmanathan, P., Gavaghan, D. J., van der Graaf, P. H., & Noble, D. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-021-00982-5 · Cited by 44
Omar, M., Jensen, J., Burkhoff, D., Frederiksen, P. H., Kistorp, C., Videbæk, L., Poulsen, M. K., Gustafsson, F., Køber, L., Borlaug, B. A., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009156 · Cited by 45
Obesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 51
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 43
Sodium glucose co-transporter 2 inhibitors and heart failure.
Ghosh, R. K., Ghosh, G. C., Gupta, M., Bandyopadhyay, D., Akhtar, T., Deedwania, P., Lavie, C. J., Fonarow, G. C., & Aneja, A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.038 · Cited by 41
SGLT2 Inhibition and Kidney Potassium Homeostasis
Palmer, B. F., & Clegg, D. J. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000300 · Cited by 41
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Yuan, L., Li, F., Fan, Y., Yu, Y., Chen, M., & Xi, J. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.020 · Cited by 42
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 43
Chloride in Heart Failure Syndrome: Its Pathophysiologic Role and Therapeutic Implication
Kataoka, H. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00238-2 · Cited by 40
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Tsampasian, V., Baral, R., Chattopadhyay, R. K., Dębski, M., Joshi, S. S., Reinhold, J., Dweck, M. R., Garg, P., & Vassiliou, V. S. (2021) · Cardiology Research and Practice · doi:10.1155/2021/9927533 · Cited by 43
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use
Siafarikas, C., Kapelios, C. J., Papatheodoridi, Μ., Vlachogiannakos, J., Tentolouris, N., & Papatheodoridis, G. (2024) · Liver International · doi:10.1111/liv.15851 · Cited by 40
Cahn, A., Raz, I., Bonaca, M. P., Mosenzon, O., Murphy, S. A., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Bhatt, D. L., McGuire, D. K., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14041 · Cited by 37
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01295-6 · Cited by 37
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Dutka, M., Bobiński, R., Ulman-Włodarz, I., Hajduga, M. B., Bujok, J., Pająk, C., & Ćwiertnia, M. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10041-1 · Cited by 40
Vallon, V. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae060 · Cited by 37
Bjornstad, P., Greasley, P. J., Wheeler, D. C., Chertow, G. M., Langkilde, A. M., Heerspink, H. J. L., & van Raalte, D. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.003 · Cited by 41
Self-citationIordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 34
Kuriyama, S. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000501081 · Cited by 33
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35
Relationship of Dapagliflozin With Serum Sodium
Yeoh, S. E., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.01.019 · Cited by 37
Self-citationDeschaine, B., Verma, S., & Rayatzadeh, H. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.11 · Cited by 34
Weir, M. R., McCullough, P. A., Buse, J. B., & Anderson, J. E. (2020) · American Journal of Nephrology · doi:10.1159/000506533 · Cited by 31
Clegg, L. E., Heerspink, H. J. L., Penland, R. C., Tang, W., Boulton, D. W., Bachina, S., Fox, R. D., Fenici, P., Thuresson, M., Mentz, R. J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1871 · Cited by 31
Self-citationRecent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 35
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312527 · Cited by 34
Kaku, K., Chin, R., Naito, Y., Iliev, H., Ikeda, R., Ochiai, K., & Yasui, A. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1694659 · Cited by 30
de la Espriella, R., Santas, E., Reiriz, I. Z., Górriz, J. L., Marcos, M. C., & Núñez, J. E. (2021) · Nefrología · doi:10.1016/j.nefro.2021.04.006 · Cited by 31
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 49
Verma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 28
Self-citationAlbulushi, A., Tanoh, D. B., Almustafa, A., Matrooshi, N. A., Zolty, R., & Lowes, B. D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02415-8 · Cited by 29
The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
Yaribeygi, H., Simental‐Mendía, L. E., Banach, M., Bo, S., & Sahebkar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109526 · Cited by 29
Sarzani, R., Giulietti, F., Pentima, C. D., & Spannella, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.030 · Cited by 30
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Gronda, E., Lopaschuk, G. D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., Gabrielli, D., & Claudio Napoli, A. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0399 · Cited by 30
Zhou, J., Lee, S., Leung, K. S. K., Wai, A. K. C., Liu, T., Liu, Y., Chang, D., Wong, W. T., Wong, I. C. K., Cheung, B. M. Y., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13830 · Cited by 28
Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 29
Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis
Galli, E., Bourg, C., Kosmala, W., Oger, E., & Donal, E. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.010 · Cited by 31
Krepostman, N., & Kramer, H. (2021) · Kidney360 · doi:10.34067/kid.0000472021 · Cited by 28
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Santos‐Ferreira, D., Gonçalves-Teixeira, P., & Fontes‐Carvalho, R. (2019) · Cardiology · doi:10.1159/000504694 · Cited by 27
Kataoka, H., & Yoshida, Y. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-0515-x · Cited by 26
Lim, J., Kwon, S., Seo, Y. J., Kim, Y., Kwon, H., Kim, D. K., Lee, H., Kim, Y.-L., Kim, C., Park, S.-H., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.05.022 · Cited by 25
BAJAJ, H. S., Raz, I., Mosenzon, O., Murphy, S. A., Rozenberg, A., Yanuv, I., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14011 · Cited by 25
Yeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25
Docherty, K. F., McDowell, K., Welsh, P. I., Osmanska, J., Anand, I. S., de Boer, R. A., Køber, L., Kosiborod, M., Martínez, F. A., O’Meara, E., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.011 · Cited by 25
Self-citationCurrent and future strategies for targeting the endothelin pathway in cardiovascular disease
Abraham, G. R., Williams, T., Maguire, J. J., Greasley, P. J., Ambery, P., & Davenport, A. P. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00347-2 · Cited by 24
Self-citationSodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Brito, D. A., Bettencourt, P., Carvalho, D. M., Ferreira, J., Fontes‐Carvalho, R., Franco, F., Moura, B., Silva‐Cardoso, J., de Melo, R. T., & Fonseca, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06973-3 · Cited by 24
Koh, E. S., Han, K., Nam, Y., Wittbrodt, E. T., Fenici, P., Kosiborod, M., Heerspink, H. J. L., Yoo, S., & Kwon, H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14239 · Cited by 24
Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome
Pastore, M. C., Stefanini, A., Mandoli, G. E., Piu, P., Diviggiano, E. E., Iuliano, M. A., Carli, L., Marchese, A., Martini, L., Pecere, A., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.05.014 · Cited by 23
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Verma, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.007 · Cited by 24
The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
Genuardi, M. V., & Mather, P. J. (2021) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447211002678 · Cited by 25
Hernandez, M., Sullivan, R. D., McCune, M. E., Reed, G. L., & Gladysheva, I. P. (2022) · Diagnostics · doi:10.3390/diagnostics12040989 · Cited by 22
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
Voorrips, S. N., Saucedo‐Orozco, H., Sánchez-Aguilera, P., de Boer, R. A., van der Meer, P., & Westenbrink, B. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158631 · Cited by 24
Miyoshi, H., Kameda, H., Yamashita, K., Nakamura, A., & Kurihara, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13064 · Cited by 21
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 23
Scheen, A. J., & Delanaye, P. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101315 · Cited by 21
Yu, H., Basu, S., & Hallow, K. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008074 · Cited by 22
Self-citationYu, J., Arnott, C. G., Neuen, B. L., Heersprink, H. J. L., Mahaffey, K. W., Cannon, C. P., Khan, S. S., Baldridge, A. S., Shah, S. J., Huang, Y., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13236 · Cited by 21
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
Delanaye, P., Wissing, K. M., & Scheen, A. J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab096 · Cited by 21
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
Angé, M., Poortere, J. D., Ginion, A., Battault, S., Dechamps, M., Muccioli, G. G., Roumain, M., Morelle, J., Druart, S., Mathivet, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93156-1 · Cited by 21
Brata, R. D., Paşcalău, A. V., Frățilă, O., Paul, I. L., Muresan, M. M., Cămărășan, A., & Ilias, T. I. (2024) · Healthcare · doi:10.3390/healthcare12232464 · Cited by 21
Srinivas, N., Sarnaik, M. K., Modi, S., Pisipati, Y., Vaidya, S., Gaggatur, N. S., Sange, A. H., & Sange, I. (2021) · Cureus · doi:10.7759/cureus.16868 · Cited by 22
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Kansara, A., Mubeen, F., & Shakil, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1120 · Cited by 22
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 20
Janjusevic, M., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Sorrentino, A., Beltrami, A. P., Sinagra, G., & Aleksova, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042336 · Cited by 21
Shetty, S. S., & KRUMERMAN, A. K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01552-2 · Cited by 20
The Importance of Optimal Hydration in Patients with Heart Failure—Not Always Too Much Fluid
Wittczak, A., Ślot, M., & Bielecka-Dabrowa, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102684 · Cited by 22
Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study
Singh, V., De, A., Aggrawal, R., Singh, A. K., Charak, S., & Bhagat, N. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08667-4 · Cited by 19
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 19
Dapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 19
Patoulias, D., Fragakis, N., & Rizzo, M. (2022) · Life · doi:10.3390/life12122062 · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 19
Beal, B., Schutte, A. E., & Neuen, B. L. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01281-1 · Cited by 21
Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure
de la Espriella, R., Miñana, G., Santas, E., Núñez, G., Lorenzo, M., Núñez, E., Bayés‐Genís, A., & Núñez, J. E. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.06.045 · Cited by 18
Monnerat, S., Christ‐Crain, M., & Refardt, J. C. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01138-4 · Cited by 22
Rasalam, R. R., Atherton, J. J., Deed, G., Molloy‐Bland, M., Cohen, N. D., & Sindone, A. P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13483 · Cited by 17
A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date
Tang, H., Xu, C., Zhang, P., Luo, T., Huang, Y., & Yang, X. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106415 · Cited by 17
Berton, A. M., Parasiliti‐Caprino, M., Prencipe, N., Bioletto, F., Lopez, C., Bona, C., Caputo, M., Rumbolo, F., Ponzetto, F., Settanni, F., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1098404 · Cited by 17
d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 18
Bapir, R., Bhatti, K. H., Eliwa, A., García‐Perdomo, H. A., Gherabi, N., Hennessey, D. B., Magri, V., Mourmouris, P., Ouattara, A., Perletti, G., et al. (2023) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2023.11509 · Cited by 18
Lam-Chung, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174692 · Cited by 17
Asakura, M., Masuda, T., Oka, K., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., Shimada, K., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14111194 · Cited by 17
Smeijer, J. D., Wasehuus, V. S., Dhaun, N., Górriz, J. L., Soler, M. J., Åstrand, M., Mercier, A., Greasley, P. J., Ambery, P., & Heerspink, H. J. L. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000436 · Cited by 17
Self-citationExploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 21
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
Metabolic Approaches for the Treatment of Dilated Cardiomyopathy
Spoladore, R., Pinto, G., Daus, F., Pezzini, S., Kolios, D., & Fragasso, G. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070287 · Cited by 15
Park, S., Jeong, H. E., Lee, H., You, S. C., & Shin, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01896-3 · Cited by 17
Li, Z., Xu, X. J., Deng, L., Liao, R., Liang, R., Zhang, B., & Zhang, L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.017 · Cited by 16
Nakatsukasa, T., Ishizu, T., Ouchi, M., Murakoshi, N., Sato, K., Yamamoto, M., Kawanishi, K., Seo, Y., & Ieda, M. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0105 · Cited by 16
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., Chiang, F., & Tu, Y. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad078 · Cited by 16
Zhan, X., Cheng, L., Huo, N., Yu, L., Liu, C., Liu, T., Li, G., & Fu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.908037 · Cited by 15
Metadata
- Authors
- Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W.
- Affiliations
- University of Georgia (US)
- AstraZeneca (United States) (US)
- AstraZeneca (Sweden) (SE)
- University of Glasgow (GB)
- Corresponding author
- Hallow, Karen M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-11-15
- Volume
- 20
- Issue
- 3
- Pages
- 479-487
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2763866789
- Cited by
- 499
- References
- 24
- Citations by year
- 2026: 36 · 2025: 50 · 2024: 46 · 2023: 75 · 2022: 65 · 2021: 89 · 2020: 76 · 2019: 44 · 2018: 15
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SGLT2 inhibitors, dapagliflozin, heart failure hospitalization, interstitial fluid volume, osmotic diuresis, fluid congestion, loop diuretics, bumetanide, EMPA-REG OUTCOME
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adult, Benzhydryl Compounds, Blood Volume, Bumetanide, Diuresis, Diuretics, Drug Combinations, Drug Interactions, Female, Glucosides, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Osmolar Concentration, Sodium, Water-Electrolyte Imbalance, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
